CTNY Competitors

Organogenesis™ is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Acelity is a global advanced wound care company, offering innovative solutions from the hospital to home that improve the lives of patients in more than 90 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. Our shared values drive our company’s personality, culture and priorities by providing a framework for making decision: Customer First, Integrity, A Will to Win, One Acelity. We are the undisputed leader in negative pressure wound therapy and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with nearly 5,000 employees around the globe. This channel and specific content are intended for a global audience. Patients should consult with their healthcare providers regarding their specific medical conditions, treatments, information on this channel, and risks and benefits of Acelity products. This channel is not a substitute for professional medical advice, diagnosis, or treatment. Not all Acelity products are available in all countries. Acelity is not responsible for, and does not control/endorse materials such as linked 3rd party videos, sites or ads, and makes no representations regarding their accuracy.